
- Oncology NEWS International Vol 11 No 9
- Volume 11
- Issue 9
FDA Clears NMP22 BladderChek for Monitoring of Bladder Cancer
NEWTON, Mass-Matritech Inc. has received clearance from the US Food and Drug Administration to market NMP22 BladderChek for monitoring patients with a history of bladder cancer.
NEWTON, MassMatritech Inc. has received clearance from the US Food and Drug Administration to market NMP22 BladderChek for monitoring patients with a history of bladder cancer.
The test brings rapid detection into the urologist’s office through the use of proteomics technology, the company said in a news release. Four drops of urine are placed on the BladderChek cassette to detect the presence of NMP22, a nuclear matrix protein correlated with bladder cancer.
Clinical trial results reviewed by the FDA showed that NMP22 Bladder-Chek detected 4 times more early-stage bladder tumors and 2.5 times more life-threatening, high-grade tumors than cytology. The test is used in conjunction with cystoscopy.
Articles in this issue
about 23 years ago
Tumor-Specific Idiotype Vaccines Promising in B-Cell Lymphomasabout 23 years ago
Childhood Survivors May Not Know Their Past Rxabout 23 years ago
Pemetrexed/Gemcitabine Promising in Advanced Pancreatic Cancerabout 23 years ago
Physician Experience Predicts HIV-Related Mortalityabout 23 years ago
Preliminary Phase III Results for Provenge Vaccine in Prostate Cancerabout 23 years ago
Eloxatin With 5-FU/LV Approved for Recurrent Colon Cancerabout 23 years ago
Comprehensive Geriatric Evaluations Improve Careabout 23 years ago
Nordion’s Monte Carlo Dose Calculation Software Approvedabout 23 years ago
No Strong Link Between Breast Cancer Risk and Pollutantsabout 23 years ago
Imatinib Inactive in Sarcomas That Lack C-KIT/PDGFNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.